Biology of vascular endothelial growth factor and its receptors in head and neck cancer: Beyond angiogenesis

Head and Neck

Volumn 33, Issue 8, 2011, Pages 1220-1229

  Christopoulos, Apostolos ^a   Ahn, Sun M ^b   Klein, Jonah D ^b   Kim, Seungwon ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

angiogenesis; autocrine; head and neck; VEGF; VEGFR

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONOCLONAL ANTIBODY DC101; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE; SEMAXANIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CHEMORADIOTHERAPY; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG RESPONSE; GENE EXPRESSION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MICROVASCULAR ENDOTHELIAL CELL; MOLECULARLY TARGETED THERAPY; NEOPLASM; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; THERAPY RESISTANCE; TUMOR GROWTH; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; FEMALE; HEAD AND NECK TUMOR; HUMAN; MALE; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960389739     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21588     Document Type: Article

References (88)

1. Davies L, Welch HG,. Epidemiology of head and neck cancer in the United States. Otolaryngol Head Neck Surg 2006; 135: 451-457.
2. Haddad RI, Shin DM,. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-1154.
3. Cruz JJ, Ocana A, Del Barco E, Pandiella A,. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 2007; 18: 421-430. (Pubitemid 46359619)
4. Hicklin DJ, Ellis LM,. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027. (Pubitemid 46202320)
5. Holmes K, Roberts OL, Thomas AM, Cross MJ,. Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal 2007; 19: 2003-2012. (Pubitemid 47354167)
6. Ferrara N, Gerber HP, LeCouter J,. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676. (Pubitemid 36749215)
7. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z,. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22. (Pubitemid 29038270)
8. Savvides P, Greskovich J, Bokar J, et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). Abstracts of the 2007 Multidisciplinary Head and Neck Cancer Symposium 2007: 1.
9. Vokes EE, Cohen EE, Mauer AM, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol (Meeting Abstracts) 2005; 23: 5504 (abstract).
10. Fujita K, Sano D, Kimura M, et al. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2007; 18: 47-51.
11. Sano D, Kawakami M, Fujita K, et al. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 2007; 17: 289-295.
12. Folkman J,. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
13. Bouck N, Stellmach V, Hsu SC,. How tumors become angiogenic. Adv Cancer Res 1996; 69: 135-174. (Pubitemid 26274885)
14. Paku S,. Current concepts of tumor-induced angiogenesis. Pathol Oncol Res 1998; 4: 62-75. (Pubitemid 28257201)
15. Fidler IJ, Ellis LM,. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-188. (Pubitemid 24324908)
16. Riedel F, Gotte K, Schwalb J, Wirtz H, Bergler W, Hormann K,. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 2000; 257: 332-336. (Pubitemid 30612326)
17. Shemirani B, Crowe DL,. Head and neck squamous cell carcinoma lines produce biologically active angiogenic factors. Oral Oncol 2000; 36: 61-66.
18. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG,. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 2000; 18: 2046-2052. (Pubitemid 30324357)
19. Lentsch EJ, Goudy S, Sosnowski J, Major S, Bumpous JM,. Microvessel density in head and neck squamous cell carcinoma primary tumors and its correlation with clinical staging parameters. Laryngoscope 2006; 116: 397-400. (Pubitemid 44318099)
20. Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E,. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 1997; 33: 369-374. (Pubitemid 28129241)
21. Boonkitticharoen V, Kulapaditharom B, Leopairut J, et al. Vascular endothelial growth factor A and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2008; 134: 1305-1311.
22. Tse G, Chan A, Yu K, et al. Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma. Ann Surg Oncol 2007; 14: 3558-3565. (Pubitemid 350160145)
23. Ferrara N,. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9: 2-10. (Pubitemid 38747842)
24. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275. (Pubitemid 29246458)
25. Maxwell PH, Ratcliffe PJ,. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 2002; 13: 29-37. (Pubitemid 35418312)
26. Ellis LM,. The role of neuropilins in cancer. Mol Cancer Ther 2006; 5: 1099-1107. (Pubitemid 43881301)
27. Riedel F, Götte K, Li M, Hörmann K, Grandis J,. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo. Int J Oncol 2003; 23: 577-583.
28. Kim J, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844. (Pubitemid 23132159)
29. Mayer RJ,. Two steps forward in the treatment of colorectal cancer. N Engl J Med 2004; 350: 2406-2408. (Pubitemid 38702852)
30. Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
31. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. (Pubitemid 38702844)
32. Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009; 15: 3484-3494.
33. Epstein RJ,. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 2007; 26: 443-452. (Pubitemid 350115101)
34. Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009; 15: 3484-3494.
35. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134. (Pubitemid 46089673)
36. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799. (Pubitemid 46224178)
37. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 2544-2555.
38. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23: 8033-8040. (Pubitemid 46657405)
39. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS,. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
40. PÃez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
41. Sini P, Samarzija I, Baffert F, et al. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics. Cancer Res 2008; 68: 1581-1592. (Pubitemid 351346868)
42. Verheul HMW, Hammers H, van Erp K, et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007; 13: 4201-4208. (Pubitemid 47105984)
43. Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006; 12: 2197-2207.
44. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25: 4557-4561. (Pubitemid 350035312)
45. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results: from a two-part, double-blind, randomized phase II study. J Clin Oncol 2009; 27: 2523-2529.
46. Heymach J, Johnson B, Prager D, Csada E, Roubec J, Pesek M,. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25: 4270-4277. (Pubitemid 47548567)
47. Yigitbasi OG, Younes MN, Doan D, et al. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 2004; 64: 7977-7984. (Pubitemid 39446932)
48. Meluch A, Spigel D, Burris H, et al. Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck. J Clin Oncol (Meeting Abstracts) 2009; 27: 6012 (abstract).
49. Pfister D, Lee N, Sherman E, et al. Phase II study of bevacizumab (B) plus cisplatin (C) plus intensity-modulated radiation therapy (IMRT) for locoregionally advanced head and neck squamous cell cancer (HNSCC): Preliminary Results: J Clin Oncol (Meeting Abstracts) 2009; 27: 6013 (abstract).
50. Papadimitrakopoulou V, Frank S, Blumenschein G, et al. Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol (Meeting Abstracts) 2009; 27: 6016 (abstract).
51. Gibson M, Kies M, Kim S, et al. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: an updated report. J Clin Oncol (Meeting Abstracts) 2009; 27: 6049 (abstract).
52. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10: 247-257.
53. Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 2010; 65: 649-660.
54. Choong N, Cohen E, Kozloff M, et al. Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol (Meeting Abstracts). 2008; 26: 6064 (abstract).
55. Feinstein T, Raez L, Rajasenan K, et al. Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): updated Results: of a phase II trial. J Clin Oncol (Meeting Abstracts). 2008; 26: 6069 (abstract).
56. Williamson S, Moon J, Huang C, Guaglianone P, Wolf G, Urba S,. A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): a Southwest Oncology Group (SWOG) trial. J Clin Oncol (Meeting Abstracts) 2007; 25: 6044 (abstract).
57. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-3773. (Pubitemid 47372619)
58. Fury MG, Zahalsky A, Wong R, et al. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 2007; 25: 165-172. (Pubitemid 46020876)
59. Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D,. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005; 24: 8025-8037. (Pubitemid 41746746)
60. Bachelder RE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001; 61: 5736-5740. (Pubitemid 32769088)
61. Bachelder RE, Wendt MA, Mercurio AM,. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002; 62: 7203-7206. (Pubitemid 36025239)
62. Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005; 24: 2647-2653. (Pubitemid 40593092)
63. Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST,. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2005; 65: 3691-3699. (Pubitemid 40616346)
64. Wey JS, Fan F, Gray MJ, et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 2005; 104: 427-438. (Pubitemid 40993273)
65. Yang AD, Camp ER, Fan F, et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 2006; 66: 46-51. (Pubitemid 43166007)
66. Jackson MW, Roberts JS, Heckford SE, et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002; 62: 854-859. (Pubitemid 34126964)
67. Neuchrist C, Erovic BM, Handisurya A, et al. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 2001; 111: 1834-1841. (Pubitemid 32946463)
68. Kyzas PA, Cunha IW, Ioannidis JP,. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005; 11: 1434-1440. (Pubitemid 40315223)
69. Bock JM, Sinclair LL, Bedford NS, Jackson RE, Lee JH, Trask DK,. Modulation of cellular invasion by VEGF-C expression in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2008; 134: 355-353.
70. Lucas J, Slomiany M, Young R, Schey K, Rozenzweig S,. HEF1 mediates VEGFA165 induced metastatic potential in head and neck squamous cell carcinoma. 6th Annual Head and Neck Multidisciplinary Research Workshop (Meeting Abstract) 2008.
71. Tong M, Lloyd B, Pei P, Mallery SR,. Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF. J Cell Biochem 2008; 105: 1202-1210.
72. Ahn S, Christopoulos A, Klein J, Kim S,. Pro-tumorigenic autocrine role of vascular endothelial growth factor in head and neck squamous cell carcinoma. American Head and Neck Society Annual Meeting 2009 (abstract).
73. Barr MP, Byrne AM, Duffy AM, et al. A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1- expressing breast tumour cells. Br J Cancer 2005; 92: 328-333. (Pubitemid 40343149)
74. Timoshenko AV, Rastogi S, Lala PK,. Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br J Cancer 2007; 97: 1090-1098. (Pubitemid 47587011)
75. Weigand M, Hantel P, Kreienberg R, Waltenberger J,. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 2005; 8: 197-204. (Pubitemid 41759144)
76. Lesslie DP, Summy JM, Parikh NU, et al. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 2006; 94: 1710-1717. (Pubitemid 43924937)
77. Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G,. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 2008; 68: 285-291. (Pubitemid 351380130)
78. Mulkeen AL, Silva T, Yoo PS, et al. Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells. Arch Surg 2006; 141: 367-274.
79. Bates RC, Goldsmith JD, Bachelder RE, et al. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol 2003; 13: 1721-1727. (Pubitemid 37216251)
80. Gray MJ, Van Buren G, Dallas NA, et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst 2008; 100: 109-120. (Pubitemid 351480563)
81. Castro-Rivera E, Ran S, Thorpe P, Minna JD,. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci U S A 2004; 101: 11432-11437. (Pubitemid 39038364)
82. Das B, Yeger H, Tsuchida R, et al. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 2005; 65: 7267-7275. (Pubitemid 41161258)
83. Vieira JM, Santos SC, Espadinha C, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol 2005; 153: 701-709. (Pubitemid 41672417)
84. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 769-777. (Pubitemid 46622044)
85. Shang ZJ, Li ZB, Li JR,. VEGF is up-regulated by hypoxic stimulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: in vitro and in vivo studies. Int J Oral Maxillofac Surg 2006; 35: 533-538.
86. Dunst J, Stadler P, Becker A, et al. Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol 2001; 177: 469-473. (Pubitemid 32861427)
87. Lalla RV, Boisoneau DS, Spiro JD, Kreutzer DL,. Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2003; 129: 882-888. (Pubitemid 36966435)
88. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ,. Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol 2005; 18: 485-494. (Pubitemid 40478111)